Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor-drug and receptor-gene interactions

Molecular Endocrinology

Volumn 24, Issue 6, 2010, Pages 1287-1296

  Holbeck, Susan ^a   Chang, Jianjun ^c   Best, Anne M ^c   Bookout, Angie L ^b   Mangelsdorf, David J ^b,c   Martinez, Elisabeth D ^b,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 TERT BUTYL 20 DEOXYVINBLASTINE; 2,3 DIDEMETHYL COLCHICINE; 3 DIMETHYL 3 BUTYL THIOCOLCHICINE; 4 OXOISOTRETINOIN; 6 ALPHA,9 DIFLUOROPREDNISOLONE; 7 EPI 10 DEACETYLTAXOL; ALLOCOLCHICINE; ANTINEOPLASTIC AGENT; BISANTRENE; BLEOMYCIN; BRUCEANTIN; CELL NUCLEUS RECEPTOR; COLCHICINE 3 DESMETHYL; DAB 389 IL 6; DAUNOMYCINONE; DEACETYLCOLCHICINE; ECTEINASCIDIN; ISOFLUPREDONE; MILTEFOSINE; NOCODAZOLE; NSC 608832; OLIVOMYCIN; PIRARUBICIN; RHIZOXIN; TAMOXIFEN; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; XANTOCILLIN;

ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER CELL CULTURE; COLON CANCER; GENE INTERACTION; HUMAN; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; MELANOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COUP TRANSCRIPTION FACTOR II; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER;

EID: 77954830442     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2010-0040     Document Type: Article

References (49)

1. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ 2006 Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126:789-799
2. O'Malley B 2008 The Year in Basic Science: nuclear receptors and coregulators. Mol Endocrinol 22:2751-2758
3. Sonoda J, Pei L, Evans RM 2008 Nuclear receptors: decoding metabolic disease. FEBS Lett 582:2-9
4. Balk SP, Knudsen KE 2008 AR, the cell cycle, and prostate cancer. Nucl Recept Signal 6:e001
5. Castagnetta L, Granata OM, Cocciadiferro L, Saetta A, Polito L, Bronte G, Rizzo S, Campisi I, Agostara B, Carruba G 2004 Sex steroids, carcinogenesis, and cancer progression. Ann NY Acad Sci 1028:233-246
6. Crescenzi A, Graziano MF, Carosa E, Papini E, Rucci N, Nardi F, Trimboli P, Calvanese A, Jannini EA, D'Armiento M 2003 Localization and expression of thyroid hormone receptors normal and neoplastic human thyroid. J Endocrinol Invest 26:1008-1012
7. Hartman J, Ström A, Gustafsson JA 2009 Estrogen receptor beta in breast cancer: diagnostic and therapeutic implications. Steroids 74: 635-641
8. Kato Y, Ying H, Willingham MC, Cheng SY 2004 A tumor suppressor role for thyroid hormone β receptor in a mouse model of thyroid carcinogenesis. Endocrinology 145:4430-4438
9. Persson I 2000 Estrogens in the causation of breast, endometrial and ovarian cancers: evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol 74:357-364
10. Shao W, Brown M 2004 Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res 6:39-52
11. Cross HS, Kállay E, Khorchide M, Lechner D 2003 Regulation of extrarenal synthesis of 1,25-dihydroxyvitamin D3-relevance for colonic cancer prevention and therapy. Mol Aspects Med 24:459-465
12. Girnun GD, Naseri E, Vafai SB, Qu L, Szwaya JD, Bronson R, Alberta JA, Spiegelman BM 2007 Synergy between PPARγ ligands and platinum-based drugs in cancer. Cancer Cell 11:395-406 (Pubitemid 46670076)
13. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM 1998 Terminal differentiation of human breast cancer through PPARγ. Mol Cell 1:465-470
14. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW 2000 Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 97:10990-10995
15. Nwankwo JO, Robbins ME 2001 Peroxisome proliferator-activated receptor- gamma expression in human malignant and normal brain, breast and prostate-derived cells. Prostaglandins Leukot Essent Fatty Acids 64:241-245
16. Virmani AK, Rathi A, Zöchbauer-Müller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD, Gazdar AF 2000 Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas. J Natl Cancer Inst 92: 1303-1307
17. Xu XC, Sozzi G, Lee JS, Lee JJ, Pastorino U, Pilotti S, Kurie JM, Hong WK, Lotan R 1997 Suppression of retinoic acid receptor β in non-small-cell lung cancer in vivo: implications for lung cancer development. J Natl Cancer Inst 89:624-629
18. Kliewer SA, Goodwin B, Willson TM 2002 The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 23:687-702
19. You L 2004 Steroid hormone biotransformation and xenobiotic induction of hepatic steroid metabolizing enzymes. Chem Biol Interact 147:233-246
20. Sengupta S, Wasylyk B 2004 Physiological and pathological consequences of the interactions of the p53 tumor suppressor with the glucocorticoid, androgen, and estrogen receptors. Ann NY Acad Sci 1024:54-71
21. Zhang CL, Zou Y, He W, Gage FH, Evans RM 2008 A role for adult TLX-positive neural stem cells in learning and behaviour. Nature 451:1004-1007
22. Shi Y, Chichung Lie D, Taupin P, Nakashima K, Ray J, Yu RT, Gage FH, Evans RM 2004 Expression and function of orphan nuclear receptor TLX in adult neural stem cells. Nature 427:78-83
23. Ellison G, Klinowska T, Westwood RF, Docter E, French T, Fox JC 2002 Further evidence to support the melanocytic origin of MDA-MB-435. Mol Pathol 55:294-299
24. Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD 2007 MDA-MB-435 cells are derived from M14 melanoma cells: a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104:13-19
25. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO 2000 Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24:227-235
26. Liscovitch M, Ravid D 2007 A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. Cancer Lett 245:350-352
27. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR 2005 Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117-122
28. List HJ, Smith CL, Martinez E, Harris VK, Danielsen M, Riegel AT 2000 Effects of antiandrogens on chromatin remodeling and transcription of the integrated mouse mammary tumor virus promoter. Exp Cell Res 260:160-165
29. Prakash P, Russell RM, Krinsky NI 2001 In vitro inhibition of proliferation of estrogen-dependent and estrogen-independent human breast cancer cells treated with carotenoids or retinoids. J Nutr 131:1574-1580
30. Toma S, Isnardi L, Raffo P, Dastoli G, De Francisci E, Riccardi L, Palumbo R, Bollag W 1997 Effects of all-trans-retinoic acid and 13-cis-retinoic acid on breast-cancer cell lines: growth inhibition and apoptosis induction. Int J Cancer 70:619-627
31. Hua S, Kittler R, White KP 2009 Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell 137: 1259-1271
32. Chao HH, Liu JC, Hong HJ, Lin JW, Chen CH, Cheng TH 23 June 2009 L-Carnitine reduces doxorubicin-induced apoptosis through a prostacyclin- mediated pathway in neonatal rat cardiomyocytes. Int J Cardiol 10.1016/j.i.card.2009.06.010
33. Lin H, Hou CC, Cheng CF, Chiu TH, Hsu YH, Sue YM, Chen TH, Hou HH, Chao YC, Cheng TH, Chen CH 2007 Peroxisomal proliferator-activated receptor-α protects renal tubular cells from doxorubicin-induced apoptosis. Mol Pharmacol 72:1238-1245
34. Mitra MS, Donthamsetty S, White B, Latendresse JR, Mehendale HM 2007 Mechanism of protection of moderately diet restricted rats against doxorubicin-induced acute cardiotoxicity. Toxicol Appl Pharmacol 225:90-101
35. You LR, Lin FJ, Lee CT, DeMayo FJ, Tsai MJ, Tsai SY 2005 Suppression of Notch signalling by the COUP-TFII transcription factor regulates vein identity. Nature 435:98-104
36. Lee CT, Li L, Takamoto N, Martin JF, Demayo FJ, Tsai MJ, Tsai SY 2004 The nuclear orphan receptor COUP-TFII is required for limb and skeletal muscle development. Mol Cell Biol 24:10835-10843 (Pubitemid 39603139)
37. Zhang LJ, Liu X, Gafken PR, Kioussi C, Leid M 2009 A chicken ovalbumin upstream promoter transcription factor I (COUP-TFI) complex represses expression of the gene encoding tumor necrosis factor α-induced protein 8 (TNFAIP8). J Biol Chem 284:6156-6168
38. Azzouz S, Maache M, Garcia RG, Osuna A 2005 Leishmanicidal activity of edelfosine, miltefosine and ilmofosine. Basic Clin Pharmacol Toxicol 96:60-65
39. Barratt G, Saint-Pierre-Chazalet M, Loiseau PM 2009 Cellular transport and lipid interactions of miltefosine. Curr Drug Metab 10:247-255
40. Croft SL, Engel J 2006 Miltefosine-discovery of the antileishmanial activity of phospholipid derivatives. Trans R Soc Trop Med Hyg 100(Suppl 1):S4-S8
41. Santa-Rita RM, Henriques-Pons A, Barbosa HS, de Castro SL 2004 Effect of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against Leishmania amazonensis. J Antimicrob Chemother 54:704-710
42. Li Y, Choi M, Cavey G, Daugherty J, Suino K, Kovach A, Bingham NC, Kliewer SA, Xu HE 2005 Crystallographic identification and functional characterization of phospholipids as ligands for the orphan nuclear receptor steroidogenic factor-1. Mol Cell 17:491-502
43. Ortlund EA, Lee Y, Solomon IH, Hager JM, Safi R, Choi Y, Guan Z, Tripathy A, Raetz CR, McDonnell DP, Moore DD, Redinbo MR 2005 Modulation of human nuclear receptor LRH-1 activity by phospholipids and SHP. Nat Struct Mol Biol 12:357-363
44. Sablin EP, Blind RD, Krylova IN, Ingraham JG, Cai F, Williams JD, Fletterick RJ, Ingraham HA 2009 Structure of SF-1 bound by different phospholipids: evidence for regulatory ligands. Mol Endocrinol 23:25-34
45. Chadwick DE, Jean LF, Jamal N, Messner HA, Murphy JR, Minden MD 1993 Differential sensitivity of human myeloma cell lines and normal bone marrow colony forming cells to a recombinant diphtheria toxin-interleukin 6 fusion protein. Br J Haematol 85:25-36 (Pubitemid 23291469)
46. Kreitman RJ 2003 Recombinant toxins for the treatment of cancer. Curr Opin Mol Ther 5:44-51
47. Masood R, Lunardi-Iskandar Y, Jean LF, Murphy JR, Waters C, Gallo RC, Gill P 1994 Inhibition of AIDS-associated Kaposi's sarcoma cell growth by DAB389-interleukin 6. AIDS Res Hum Retroviruses 10:969-975 (Pubitemid 24279168)
48. Bookout AL, Cummins CL, Mangelsdorf DJ, Pesola JM, Kramer MF 2006 High-throughput real-time quantitative reverse transcription PCR. Curr Protoc Mol Biol Chapter 15:Unit 15.8
49. 1/S transition. J Biol Chem 277:29719-29729